Verseau Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Bedford, Massachusetts
Type:
sample
Technology:
sample
sample
sample
sample
About: Verseau is focused on developing the next major wave of cancer immunotherapies directed at a broad and potent reprogramming of the tumor microenvironment to attack tumors. This is accomplished by stimulating macrophages to shift their phenotype from immunosuppressive to a pro-inflammatory, anti-tumor state in a process called macrophage repolarization. Verseau developed a unique target discovery engine that leveraged patient data and computational biology to discover and validate over 20 novel macrophage targets. Verseau’s first-in-class monoclonal antibody candidates, VTX-0811 targeting PSGL-1 and VTX-1218 targeting VSIG4, are in late preclinical development and progressing toward clinical trials.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Verseau Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.